Filing Flows

Filing Flows › 8-K events › Akebia Therapeutics

Akebia Therapeutics: notice of delisting or failure to meet a listing standard

Form 8-K filed Oct 23, 2026 · items 3.01

What the filing says

On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, p

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Akebia Therapeutics at a glance

Latest quarterQ3 2026
Revenue$36.9M
Revenue Y/Y-37%
Operating margin-31.1%
IndustryPharmaceutical Preparations

Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%. The chart follows the revenue to costs, profit and cash.

Akebia Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent delisting notices

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.